Brokerages predict that Cytosorbents Corp (NASDAQ:CTSO) will post earnings of ($0.17) per share for the current quarter, according to Zacks. Five analysts have made estimates for Cytosorbents’ earnings, with estimates ranging from ($0.23) to ($0.14). Cytosorbents also reported earnings of ($0.17) per share in the same quarter last year. The firm is expected to report its next quarterly earnings report on Thursday, March 5th.
On average, analysts expect that Cytosorbents will report full-year earnings of ($0.60) per share for the current year, with EPS estimates ranging from ($0.70) to ($0.51). For the next fiscal year, analysts expect that the firm will report earnings of ($0.37) per share, with EPS estimates ranging from ($0.66) to ($0.08). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Cytosorbents.
Cytosorbents (NASDAQ:CTSO) last released its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.08). The business had revenue of $6.10 million for the quarter, compared to analyst estimates of $6.49 million. Cytosorbents had a negative return on equity of 165.00% and a negative net margin of 87.79%.
In other news, CEO Phillip P. Chan purchased 16,500 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were acquired at an average price of $3.96 per share, for a total transaction of $65,340.00. Corporate insiders own 5.60% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CTSO. Skylands Capital LLC raised its position in Cytosorbents by 7.0% in the second quarter. Skylands Capital LLC now owns 680,600 shares of the medical research company’s stock valued at $4,499,000 after purchasing an additional 44,550 shares during the period. Advisor Group Inc. raised its position in Cytosorbents by 15.8% in the second quarter. Advisor Group Inc. now owns 33,170 shares of the medical research company’s stock valued at $219,000 after purchasing an additional 4,530 shares during the period. Charles Schwab Investment Management Inc. raised its position in Cytosorbents by 31.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 81,270 shares of the medical research company’s stock valued at $538,000 after purchasing an additional 19,439 shares during the period. Avenir Corp raised its position in Cytosorbents by 66.6% in the second quarter. Avenir Corp now owns 145,300 shares of the medical research company’s stock valued at $960,000 after purchasing an additional 58,060 shares during the period. Finally, Sargent Investment Group LLC raised its position in Cytosorbents by 15.9% in the second quarter. Sargent Investment Group LLC now owns 333,910 shares of the medical research company’s stock valued at $2,207,000 after purchasing an additional 45,840 shares during the period. Institutional investors and hedge funds own 26.06% of the company’s stock.
Shares of CTSO traded up $0.35 on Friday, reaching $3.96. The stock had a trading volume of 456,929 shares, compared to its average volume of 183,852. The firm has a market capitalization of $117.05 million, a PE ratio of -7.07 and a beta of 1.64. The company has a quick ratio of 2.21, a current ratio of 2.40 and a debt-to-equity ratio of 1.88. The firm has a 50-day moving average of $4.44 and a 200 day moving average of $5.53. Cytosorbents has a twelve month low of $3.49 and a twelve month high of $9.82.
Cytosorbents Company Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
See Also: Economic Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.